News for Cabaletta Bio, Inc. (CABA)

**media[651954]**

Discover Cabaletta Bio's promising CAR T-cell therapy for autoimmune diseases! Durable efficacy, FDA support, and clinical potential make this attractive.

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ( CABA), a clinical-stage biotechnology company focused on developing and launching the fir

Texas-based TSS, Inc. (TSSI) is up over 43 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Analysts at Citi have revised their price target for Cabaletta Bio (CABA), cutting it to $13 from a previous $17, while maintaining a Buy rating on the stock. T

On May 15, 2025, analyst Yatin Suneja from Guggenheim updated their outlook on Cabaletta Bio (CABA). Guggenheim has maintained their 'Buy' rating on the stock,

Cabaletta Bio (CABA) is preparing for a Biologics License Application (BLA) submission for rese-cel, targeting an anticipated timeline of 2027. This decision co

Cash Position: Cash and cash equivalents stood at $131.8 million as of March 31, 2025, down from $164.0 million at the end of 2024.Funding Outlook: Current cas

[url="]Cellares[/url], the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption Program (TAP) on its autom

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ( CABA), a clinical-stage biotechnology company focused on developing and launching the fi

”“ Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the

”“ Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel

Cabaletta Bio’s financials and CAR T-cell therapy show potential but face risks. Discover why CABA stock is a risky yet potentially rewarding investment.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

California-based Bolt Projects Holdings, Inc. (BSLK) is up over 233 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

U.S. stock futures advanced on Friday after a day's break for Thanksgiving as investors look to end November on a high note.

Shares of Caballeta Bio Inc CABA rose by 24.38% to $3.01 apiece on Wednesday and advanced by 4.65% to $3.15 per share in after-hours trading, following an updat...

PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ( CABA), a clinical-stage biotechnology company focused on developing and launching the fi

Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on autoimmune diseases, announced Monday new and updated clinical data on CABA-201, presenting positive clinical safety and efficacy results.